Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma.

MLA

Shitara, K., et al. “Molecular Determinants of Clinical Outcomes with Pembrolizumab versus Paclitaxel in a Randomized, Open-Label, Phase III Trial in Patients with Gastroesophageal Adenocarcinoma.” Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 32, no. 9, Sept. 2021, pp. 1127–36. EBSCOhost, https://doi.org/10.1016/j.annonc.2021.05.803.

APA

Shitara, K., Özgüroğlu, M., Bang, Y.-J., Di Bartolomeo, M., Mandalà, M., Ryu, M.-H., Caglevic, C., Chung, H. C., Muro, K., Van Cutsem, E., Kobie, J., Cristescu, R., Aurora-Garg, D., Lu, J., Shih, C.-S., Adelberg, D., Cao, Z. A., & Fuchs, C. S. (2021). Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 32(9), 1127–1136. https://doi.org/10.1016/j.annonc.2021.05.803

Chicago

Shitara, K, M Özgüroğlu, Y-J Bang, M Di Bartolomeo, M Mandalà, M-H Ryu, C Caglevic, et al. 2021. “Molecular Determinants of Clinical Outcomes with Pembrolizumab versus Paclitaxel in a Randomized, Open-Label, Phase III Trial in Patients with Gastroesophageal Adenocarcinoma.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 32 (9): 1127–36. doi:10.1016/j.annonc.2021.05.803.